Preferred Name |
Candesartan |
|
Synonyms |
Candesartan CANDESARTAN 2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic Acid |
|
Definitions |
A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. Candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure. |
|
ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65284 |
|
CAS_Registry |
139481-59-7 |
|
CHEBI_ID |
CHEBI:3347 |
|
Chemical_Formula |
C24H20N6O3 |
|
code |
C65284 |
|
Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 |
|
Contributing_Source |
FDA |
|
DEFINITION |
A synthetic, benzimidazole-derived angiotensin II receptor antagonist prodrug with antihypertensive activity. Candesartan selectively competes with angiotensin II for the binding of the angiotensin II receptor subtype 1 (AT1) in vascular smooth muscle, blocking angiotensin II-mediated vasoconstriction and inducing vasodilatation. In addition, antagonism of AT1 in the adrenal gland inhibits angiotensin II-stimulated aldosterone synthesis and secretion by the adrenal cortex; sodium and water excretion increase, followed by a reduction in plasma volume and blood pressure. |
|
FDA_UNII_Code |
S8Q36MD2XX |
|
FULL_SYN |
Candesartan CANDESARTAN 2-Ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-benzoimidazole-4-carboxylic Acid |
|
label |
Candesartan |
|
Legacy Concept Name |
Candesartan |
|
Preferred_Name |
Candesartan |
|
prefixIRI |
Thesaurus:C65284 |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0717550 |
|
subClassOf |